Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCN-101 in Treatment Resistant Depression
NCT05414422Phase 2Completed
- Sponsor
- Perception Neuroscience
- Start
- Feb 2022
- Primary completion
- Nov 2022
- Modality
- Allosteric Modulators
- Countries
- 3
01
Overview
A Phase 2 trial of r-ketamine in major depressive disorder (MDD), sponsored by Perception Neuroscience. Started Feb 2022; status: completed.
02
Drugs
r-ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05414422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05414422.